Novartis Egypt Exec Blames Country's Drug-Access Woes On Policy
This article was originally published in PharmAsia News
Executive Summary
An executive of the Egypt unit of Swiss drug-maker Novartis cites three problems with India regulations he said are impeding the country's access to modern and innovative drugs.